24 Jul 2020 09:47
24 July 2020
Evgen Pharma plc
("Evgen" or "the Company")
Share option exercise and issue of equity
Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notice to exercise options over 1,015,200 ordinary shares in the Company. The options have been exercised pursuant to grants under the Company's share option plans.
Accordingly, the Company has issued and allotted 1,015,200 new ordinary shares of 0.25 pence each ("New Ordinary Shares"). The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 30 July 2020.
There are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 137,297,441. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.
Enquiries:
Evgen Pharma plc www.evgen.com | via Walbrook | ||
Barry Clare, Chairman |
| ||
Richard Moulson, CFO |
| ||
|
| ||
finnCap www.finncap.com | +44 (0)20 7220 0500 | ||
Geoff Nash / Teddy Whiley (Corporate Finance) |
| ||
Alice Lane (ECM) |
| ||
|
| ||
Walbrook PR | +44 (0)20 7933 87870 or evgen@walbrookpr.com | ||
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | ||
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/